—
C+
C+ The full Closelooknet — membership. Open the C+ overview

Dr. Reddy’s Laboratories Ltd ADR (RDY) — chart, structure and Closelooknet read

The Closelooknet read

Dr. Reddy's Laboratories makes and sells prescription and over-the-counter medicines, running three segments: Global Generics for branded and generic finished drugs, PSAI for active pharmaceutical ingredients and contract research, and an Others unit developing oncology and inflammation therapies.

Detail below: the desk's view, the earnings record, peers and the company snapshot; daily prices on the price-history tab. Agents can buy the score depth per call over HTTP 402 — see the catalogue. Research diary readings, not advice.

Pick a ticker to load its detail page.

Signals for this name

Every Closelooknet reading that exists for RDY, from the same nightly bakes the boards use. Research diary readings, not advice.

Weather around the name 4 macro readings: Money Temperature, Factor regime, Sector × region …

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 46/100 · S&P 500 fund at 50, above its 200-day averageEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-11-02
  • Factor regime Defensive rotation — low-vol leading, regime-change watchMomentum against low volatility (SPMO / SPLV): below its 50-day trend, 76th percentile of the window, -20.6% over 20 sessions. Factor regime → 2026-11-02
  • Sector × region Health care in US: +3.0% week · +11.1% month · +14.3% quarter · +26.9% yearThe Sector Engine cell this name lives in, from XLV.US; the 11 × 4 matrix shows where its sector is being bought and where it is being sold. Sector Engine → 2026-11-02
  • Sovereign pressure Index -1.63 · down 2.22 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-11-02
How it trades on rate days beta 0.50 to TLT · on the worst bond days it moved with the market

How it trades on rate days

How RDY has moved when long-dated Treasury yields rise — measured against TLT, the 20+ year Treasury fund.

  • Beta to long bonds, 1 year 0.50 — tends to move with bonds for every 1% move in TLT (20+ year Treasuries), Dr. Reddy’s Laboratories Ltd ADR moved 0.50% on average · correlation 0.18 · higher than 44% of US names
  • Beta, last 3 months 0.54 about the same as over the year
  • On the 10 worst bond days −0.80% on average against −0.74% for the S&P 500 the 10 sessions of the past year in which TLT fell most, i.e. long yields rose most
  • Latest of those days −0.73% TLT −1.29% that day 2026-09-24

Daily total returns from the adjusted price series; a TLT down day is a day long yields rose. Beta = the average move of the name for a 1% move in TLT. Past sensitivity, not a forecast. An investment diary, not a recommendation.

Who it is priced against Drug Manufacturers - Specialty & Generic · US · 8 names with week and year-to-date

Peer group

Drug Manufacturers - Specialty & Generic · US

Names in the same industry from the Closelooknet universe; scored names rank on their Closelooknet score, the rest on trend state.

Compared against RDY on the nightly bakes; the Peers tab ranks the cohort on the Closelooknet scores where it exists.

Company snapshot — Dr. Reddy’s Laboratories Ltd ADR

RDY in five paragraphs: what it makes and sells, where it sits in the Closelooknet stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Dr. Reddy's Laboratories makes and sells prescription and over-the-counter medicines, running three segments: Global Generics for branded and generic finished drugs, PSAI for active pharmaceutical ingredients and contract research, and an Others unit developing oncology and inflammation therapies. It covers therapeutic areas from cardiovascular and diabetes to dermatology and pain management. The company is headquartered in Hyderabad, India, and lists in the US through American Depositary Shares.
Where it sits in the stack
Dr. Reddy's carries no seat in our index and sits outside the layers the diary maps for the AI build-out; it belongs instead to the diary's broader pharmaceutical coverage, tracked as a generics and active-ingredients manufacturer rather than as an infrastructure name.
Who it is priced against
Closelooknet's peer group is not set for this name; by industry it sits with other specialty and generic drug manufacturers, and the market names Teva Pharmaceutical Industries as a comparable generics maker.
Why Closelooknet tracks it
It carries a Closelooknet score, with the momentum module the one the diary flags, though the reading can shift nightly; it holds no index seat and no diary quotes so far.
What the diary watches
Whether the shares stabilise against their 50-day and 200-day averages after trading well off the 52-week high, which would change how the diary reads the momentum module.

Dr. Reddy’s Laboratories Ltd ADR (RDY) trades on US exchanges, classified under Healthcare.

The Closelooknet company score reads 49/100 composite (momentum 65, quality 41, valuation 57) across 7 modules — the full breakdown, chart structure and analog history load live above.

Written from the company’s public profile and Closelooknet’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

The Street on this name 1 analyst action on the wire · latest: price target by Jefferies, 2026-10-25 · last print 2026-10-23

The Street on this name

Analyst actions and the latest print for RDY from the Closelooknet wires — third-party opinions on the record, not our readings.

  • Price target Jefferies — target 13.9 Target set to $13.9 (+5.2% to spot) 2026-10-25
  • Latest print EPS 0.12 against 0.10 expected — a +24.0% beat 2026-10-23

1 action on the analyst wire since 2026-08-13: 1 target change. Analyst wire → · Earnings wire →

Dividends and capital return trailing yield 1.04%, semi-annual · last 0.0830 USD on 2026-07-24

Dividends and capital return

What RDY pays out and buys back — distributions read from the price series, money terms from the filings.

  • Trailing 12 months 0.15 USD per share · a 1.04% yield on the 2026-11-02 close 2 distributions, paid twice a year 2026-11-02
  • Change on the year +61.0% against the prior twelve months prior twelve months 0.0915 USD per share
  • Last distribution 0.0830 USD per share as the price series records it, within days of the ex-date 2026-07-24
  • By calendar year 2025: 0.0915 USD (partial) · 2026: 0.15 USD to date first distribution recorded in the three-year window: 2025-07-25
  • Dividends paid, FY2026 7.01 bn USD 40% of earnings
  • Buybacks, FY2026 none reported
  • Share count −0.1% in FY2026 326 m USD of stock-based compensation in the year
  • Capital returned 7.01 bn USD · 22% of free cash flow dividends and buybacks together, against the year’s free cash flow

Per-share amounts are derived from the adjusted price series in the listing currency, so dates sit within days of the ex-date; filing figures come from the fundamentals feed for the last reported fiscal year. An investment diary, not a recommendation.

FAQ · from the current data · as of 2026-11-03

Quick answers

What is Dr. Reddy’s Laboratories Ltd ADR (RDY)?

Dr. Reddy’s Laboratories Ltd ADR trades as RDY on the US exchange (US) and is classified under Healthcare in the Closelooknet research universe, as of the registry build of 2026-11-03.

Is RDY in a Closelooknet index?

Not currently — Dr. Reddy’s Laboratories Ltd ADR is tracked in the Closelooknet research universe but is not a constituent of a Closelooknet functional index as of 2026-11-03.

What is Dr. Reddy’s Laboratories Ltd ADR's Closelooknet composite score?

49 out of 100, with momentum 65, quality 41 and valuation 57 sub-scores, as of 2026-11-03. Scores are Closelooknet's own research readings, not ratings or investment advice.

Where does RDY trade against its moving averages?

Dr. Reddy’s Laboratories Ltd ADR trades 12.3% above its 50-day and 7.6% above its 200-day moving average (7.1% above its 20-day). As of 2026-11-02 — a technical state from the nightly Closelooknet bake, not advice. The Technical tab carries the full row.

How does Dr. Reddy’s Laboratories Ltd ADR compare with its peers?

Against its peer group (Drug Manufacturers - Specialty & Generic · US), Dr. Reddy’s Laboratories Ltd ADR (RDY) sits 8.9% below its 52-week high, 12.3% above its 50-day average; Lantheus Holdings Inc (LNTH) is 10.3% below, GALDERMA GROUP AG (GALDY) is 1.0% below, Kiniksa Pharmaceuticals Ltd (KNSA) is 7.8% below, as of 2026-11-02. Put any of them next to RDY in the chart grid (2×1 or 2×2) and the page lays the companies side by side: performance, trend, valuation, margins and our money-flow reading.

How does Dr. Reddy’s Laboratories Ltd ADR trade when bond yields rise?

Over the past year Dr. Reddy’s Laboratories Ltd ADR had a beta of 0.50 to TLT, the long-dated Treasury fund — it tends to move with bonds, higher than 44% of US names. On the 10 sessions in which long bonds fell most it moved −0.80% on average, against −0.74% for the S&P 500. As of 2026-11-02; The "How it trades on rate days" block on this page carries the lines.

What does Dr. Reddy’s Laboratories Ltd ADR do?

Dr. Reddy's Laboratories makes and sells prescription and over-the-counter medicines, running three segments: Global Generics for branded and generic finished drugs, PSAI for active pharmaceutical ingredients and contract research, and an Others unit developing oncology and inflammation therapies. It covers therapeutic areas from cardiovascular and diabetes to dermatology and pain management. Closelooknet's peer group is not set for this name; by industry it sits with other specialty and generic drug manufacturers, and the market names Teva Pharmaceutical Industries as a comparable generics maker. (Company snapshot of 2026-09-17.)

Where does Dr. Reddy’s Laboratories Ltd ADR sit in the AI build-out?

Dr. Reddy's carries no seat in our index and sits outside the layers the diary maps for the AI build-out; it belongs instead to the diary's broader pharmaceutical coverage, tracked as a generics and active-ingredients manufacturer rather than as an infrastructure name. It carries a Closelooknet score, with the momentum module the one the diary flags, though the reading can shift nightly; it holds no index seat and no diary quotes so far. (Company snapshot of 2026-09-17.)

Does Dr. Reddy’s Laboratories Ltd ADR pay a dividend?

Dr. Reddy’s Laboratories Ltd ADR has paid 0.15 USD per share over the last twelve months, paid twice a year, a trailing yield of 1.04% on the 2026-11-02 close; the last distribution recorded in the price series was 0.0830 USD on 2026-07-24. In fiscal 2026 the company paid 7.01 bn USD in dividends, 22% of that year’s free cash flow. The share count fell 0.1% over the fiscal year. As of 2026-11-02; the "Dividends and capital return" block on this page carries the lines.

What has Wall Street done on Dr. Reddy’s Laboratories Ltd ADR recently?

The most recent analyst action on Dr. Reddy’s Laboratories Ltd ADR on the Closelooknet wire is a price target by Jefferies on 2026-10-25 (target 13.9). 1 action on the analyst wire since 2026-08-13: 1 target change. Its latest earnings print on the wire, 2026-10-23: EPS 0.12 against 0.10 expected — a +24.0% beat. Analyst actions are third-party opinions recorded by the wire, not Closelooknet readings. The “The Street on this name” block on this page lists the moves; the full feeds are the analyst wire and the earnings wire.

What does this page show?

A live price chart with SMA overlays and drawing tools for RDY, performance metrics, index-membership context and the Closelooknet structure read — an investment research diary view, not investment advice.

How to use this chart

Toolbar

  • Range — 1M to MAX on daily closes. 1D/5D switch a US stock cell to 5-minute intraday bars; index and foreign cells fall back to 1M daily with a note.
  • Grid — 1×1 up to 2×2. Cells are synchronized: pan or zoom one and the others follow the same dates; the crosshair tracks across all of them. 4 INDICES loads Rubin · HALO · AEI · AW40 side by side.
  • Type / Scale — OHLC, line or area; linear or log price axis.

Picking a series

  • Tap the box in a cell's header to browse every Closelooknet series — headline indices, sub-indices, sectors, layers of all six families — plus the constituents.
  • Or type any ticker (NVDA, 7203.T, ASML.AS …) and press Enter — it charts in the cell straight from our data lake.

Studies

  • Overlays / Oscillators rows toggle the standard set (SMA, Bollinger, RSI, MACD …) per cell.
  • Levels (stock cells) draws the structure engine's support lines — regression bands, pivot cluster, SMA-200, the active fib zone.

Drawing

  • Tap a tool (Trend, Ray, H-Line, Fib, Channel, Rect, Note), then tap the chart once per point — the shape follows your finger or cursor between taps. The chart stops panning while a tool is armed; tap the tool again to release.
  • Drawings save per symbol in this browser and travel between the terminal and the asset page.
  • Delete key removes the selected drawing · Escape cancels a half-placed one · Clear wipes the symbol.

Wave counts

  • Wave places an Elliott count: tap the origin, then each wave end. Press Enter to stop early (inside wave 3 is fine) — dotted ghost targets sketch the remaining waves at guideline ratios.
  • On stocks the scanner's machine count appears automatically in grey — it is fully editable: drag any point, double-tap a label to remove it, Delete to dismiss it for good, Adopt to bring the machine's proposal back.
  • The sequence picker switches 1-5 / A-B-C / A-E / W-X-Y-Z; 1 2 3 cycles the degree; Subdiv starts a one-degree-smaller child count inside a wave.

Sharing

  • Card exports the cell as a branded PNG — chart, drawings and levels exactly as shown.

Related in the Closelooknet universe

then Drug Manufacturers - Specialty & Generic. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.